The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic

Dermatol Ther. 2020 Jul;33(4):e13524. doi: 10.1111/dth.13524. Epub 2020 Jun 5.

Authors

Monica Shah¹, Muskaan Sachdeva¹, Roni P Dodiuk-Gad^{2

3

4}

Affiliations

¹ Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
³ Department of Dermatology, Ha'emek Medical Center, Afula, Israel.
⁴ Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.

No abstract available

Publication types

Letter

MeSH terms

Antimalarials / supply & distribution
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Comorbidity
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Humans
Hydroxychloroquine / supply & distribution*
Pandemics*
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
SARS-CoV-2
Skin Diseases / drug therapy
Skin Diseases / epidemiology*

Substances

Antimalarials
Hydroxychloroquine